Tarsus Pharmaceuticals (TARS) Research & Development (2019 - 2026)

Tarsus Pharmaceuticals' Research & Development history runs 8 years deep, the most recent figure standing at $22.4 million for Q1 2026.

• In Q1 2026, Research & Development rose 55.12% year-over-year to $22.4 million; the TTM figure through Mar 2026 stood at $72.3 million (up 29.67% YoY), while the FY2025 annual figure was $64.3 million, up 20.48% from the prior year.
• Research & Development was $22.4 million for Q1 2026 at Tarsus Pharmaceuticals, up from $18.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $22.4 million in Q1 2026 to a low of $500000.0 in Q4 2022.
• Historically, Research & Development has averaged $12.7 million across 5 years, with a median of $12.4 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Research & Development tumbled 93.78% in 2022, then soared 2561.0% in 2023.
• A 5-year view of Research & Development shows it stood at $500000.0 in 2022, then jumped by 2561.0% to $13.3 million in 2023, then climbed by 26.82% to $16.9 million in 2024, then climbed by 6.89% to $18.0 million in 2025, then advanced by 23.93% to $22.4 million in 2026.
• The last three Research & Development figures came in at $22.4 million (Q1 2026), $18.0 million (Q4 2025), and $16.3 million (Q3 2025), per Business Quant data.